eFFECTOR Therapeutics Announces Clinical Collaboration with Merck to Conduct a Phase 2 Combination T
top of page
Companies in the News
SAN DIEGO, Oct. 16, 2018 /PRNewswire/ -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators...
- Oct 2, 2018
FierceBiotech names Gossamer Bio as one of its “Fierce 15” biotech companies of 2018
San Diego, CA – October 2, 2018 – Gossamer Bio, Inc. (“Gossamer Bio”) today announced that it has been named by FierceBiotech as one of...
- Sep 28, 2018
Gritstone Oncology Announces Pricing of Initial Public Offering
EMERYVILLE, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq:GRTS) today announced the pricing of its initial...
- Sep 20, 2018
Indigo Agriculture Launches Indigo Certified Crops™, an Offer to Increase Grower Profitability and M
Indigo Certified Crops™ is a new offer for U.S. growers, integrating the company’s microbial and digital technologies with the newly...
- Sep 18, 2018
Indigo Agriculture Raises an Additional $250M and Launches Digital Grain Marketplace
Indigo extends efforts to decommoditize agriculture with launch of Indigo Marketplace™, a digital platform for buying and selling grain...
- Sep 13, 2018
Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of Nevanimibe in Patients with
ANN ARBOR, Mich., September 13, 2018 – Millendo Therapeutics, Inc., a clinicalstage biopharmaceutical company focused on developing novel...
- Sep 13, 2018
2018 Indigo Wheat™ Harvest Data Demonstrates Significant Yield and Quality Improvements Across more
Leveraging satellite technology, Indigo releases data on an unprecedented 40,000+ acres from the 2018 commercial wheat harvest Indigo...
- Aug 23, 2018
bluebird bio and Gritstone Oncology Announce Strategic Collaboration to Develop Novel Cancer Cell Th
CAMBRIDGE, Mass. & EMERYVILLE, Calif.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) and Gritstone Oncology, Inc. today announced a...
- Aug 10, 2018
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Compan
Transaction to Advance Millendo’s Compelling Pipeline of Late-Stage Programs for Orphan Endocrine Diseases Including Prader-Willi...
bottom of page